GLENMARK LIFE SCIENCES IPO ANALYSIS
Glenmark Life Sciences incorporated in 2011. It is the leading manufacturer of Active Pharmaceutical Ingredients. The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty pharmaceutical companies. The company’s products are sold in India and also exported to multiple countries i.e., Europe, North America, Latin America, Japan, etc.
The company is in the business of making high-quality drugs by unlocking the possibilities of science. They have established strong relationships with leading global generic pharmaceutical companies that have helped them to expand their product offerings and geographic reach. Powered by their massive, world-class manufacturing and research capabilities, they supply high-quality APIs to more than 540 pharma companies in multiple countries.
In the year 2021 till now they have achieved milestone of 403 cumulative drug master files (DMFs) across multiple markets globally. The company also contributes to global sustainability initiatives in remarkable and innovative ways, with an aim to give back more than they receive and to create positive long-term changes in the communities, regions, and geographies.
For FY 21, the company had total assets of Rs 19,970.75 million and a Revenue of Rs. 18,859.76 million. Both assets & revenue showed an increase from the past two financial years, which is a good sign. The opening IPO date is 27th July 2021 till 29th July 2021, with the IPO price of Rs 695 to Rs 720 per equity share. The issue size of the IPO is supposed to be 1513.60 Cr. Considering the price and other factors; IPO stands out to be a good investment option.
